Catherine Kim1, Elizabeth Barrett-Connor2, Vanita R Aroda3, Kieren J Mather4, Costas A Christophi5, Edward S Horton6, Xavier Pi-Sunyer7, George A Bray8, Fernand Labrie9, Sherita Hill Golden10. 1. University of Michigan, Ann Arbor, MI, United States. Electronic address: cathkim@umich.edu. 2. University of California San Diego, La Jolla, CA, United States. 3. MedStar Health Research Institute, Hyattsville, MD, United States. 4. Indiana University, Indianapolis, IN, United States. 5. George Washington University, Rockville, MD, United States. 6. Joslin Diabetes Center, Boston, MA, United States. 7. Columbia University, New York City, NY, United States. 8. Louisiana State University, Baton Rouge, LA, United States. 9. Endoceutics, Quebec, Canada. 10. Johns Hopkins University, Baltimore, MD, United States.
Abstract
OBJECTIVE: We examined associations between intensive lifestyle intervention (ILS) and changes in testosterone and associations with mood among middle-aged men. DESIGN: Secondary analysis of men (n=886) participating in the Diabetes Prevention Program which randomized glucose-intolerant, overweight men toILS, metformin, or placebobetween 1996 and 1999. MAIN OUTCOME MEASURES: Changes in testosterone between baseline and 1-year follow-up asnd associations of these changes with mood measures (Beck Depression Inventory [BDI-II], Beck Anxiety Inventory [BAI]). RESULTS:Median baseline testosterone was 10.98nmol/l and 44% (n=385) had testosterone<10.41nmol/l or 300ng/dl. Testosterone increases were greater among men randomized to ILS vs. metformin vs. placebo (1.15nmol/l vs. -0.12nmol/l vs. -0.27nmol/l, p<0.001). The association between changes in testosterone and mood differed by study arm (p<0.001 for interaction); there were no significant associations between changes in testosterone and mood changes among men in the ILS or placebo arms. Among men in the metformin arm, increases in testosterone were significantly associated with decreases in BDI-II (improved depressive symptoms) (β-coefficient -0.2336, p=0.0002) indicating a 0.23 decrease in BDI-II for every 1nmol/l increase in testosterone and decreases in BAI (improved anxiety symptoms) (β-coefficient -0.2147, p=0.0014). Similar patterns were observed for bioavailable testosterone. CONCLUSIONS: Among overweight middle-aged men with glucose-intolerance, ILS increased endogenous testosterone slightly but without significant improvements in mood. Metformin did not increase testosterone, but among metformin users, testosterone increases were associated with improvements in mood. Thus, interventions that increase endogenous testosterone may not also improve mood.
RCT Entities:
OBJECTIVE: We examined associations between intensive lifestyle intervention (ILS) and changes in testosterone and associations with mood among middle-aged men. DESIGN: Secondary analysis of men (n=886) participating in the Diabetes Prevention Program which randomized glucose-intolerant, overweight men to ILS, metformin, or placebo between 1996 and 1999. MAIN OUTCOME MEASURES: Changes in testosterone between baseline and 1-year follow-up asnd associations of these changes with mood measures (Beck Depression Inventory [BDI-II], Beck Anxiety Inventory [BAI]). RESULTS: Median baseline testosterone was 10.98nmol/l and 44% (n=385) had testosterone<10.41nmol/l or 300ng/dl. Testosterone increases were greater among men randomized to ILS vs. metformin vs. placebo (1.15nmol/l vs. -0.12nmol/l vs. -0.27nmol/l, p<0.001). The association between changes in testosterone and mood differed by study arm (p<0.001 for interaction); there were no significant associations between changes in testosterone and mood changes among men in the ILS or placebo arms. Among men in the metformin arm, increases in testosterone were significantly associated with decreases in BDI-II (improved depressive symptoms) (β-coefficient -0.2336, p=0.0002) indicating a 0.23 decrease in BDI-II for every 1nmol/l increase in testosterone and decreases in BAI (improved anxiety symptoms) (β-coefficient -0.2147, p=0.0014). Similar patterns were observed for bioavailable testosterone. CONCLUSIONS: Among overweight middle-aged men with glucose-intolerance, ILS increased endogenous testosterone slightly but without significant improvements in mood. Metformin did not increase testosterone, but among metformin users, testosterone increases were associated with improvements in mood. Thus, interventions that increase endogenous testosterone may not also improve mood.
Authors: Guy G T'Sjoen; Sara De Vos; Stefan Goemaere; Inge Van Pottelbergh; Michel Dierick; Cees Van Heeringen; Jean-Marc Kaufman Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Thomas G Travison; Andre B Araujo; Varant Kupelian; Amy B O'Donnell; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2006-12-05 Impact factor: 5.958
Authors: Molly M Shores; Victoria M Moceri; Kevin L Sloan; Alvin M Matsumoto; Daniel R Kivlahan Journal: J Clin Psychiatry Date: 2005-01 Impact factor: 4.384
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: Susan A Hall; Gretchen R Esche; Andre B Araujo; Thomas G Travison; Richard V Clark; Rachel E Williams; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2008-07-29 Impact factor: 5.958
Authors: Devina Joshi; Natasja M van Schoor; Willem de Ronde; Laura A Schaap; Hannie C Comijs; Aartjan T F Beekman; Paul Lips Journal: Clin Endocrinol (Oxf) Date: 2009-05-25 Impact factor: 3.478
Authors: Catherine Kim; Dana Dabelea; Rita R Kalyani; Costas A Christophi; George A Bray; Xavier Pi-Sunyer; Christine H Darwin; Swaytha Yalamanchi; Elizabeth Barrett-Connor; Sherita Hill Golden; Edward J Boyko Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Miriam Pillerová; Veronika Borbélyová; Michal Pastorek; Vladimír Riljak; Július Hodosy; Karyn M Frick; L'ubomíra Tóthová Journal: Front Psychiatry Date: 2022-09-08 Impact factor: 5.435